Cosmo I Building Health Confidence

Cosmo #𝗛𝟭𝟮𝟬𝟮𝟲: Strong Recurring Revenue Growth, Pipeline Advancement, and Solid #Financial Position 𝗝𝗼𝗶𝗻 𝘁𝗵𝗲 𝘄𝗲𝗯𝗰𝗮𝘀𝘁 𝘁𝗼𝗱𝗮𝘆 𝗮𝘁 𝟯:𝟬𝟬 𝗽𝗺 𝗖𝗘𝗧. HY Report 2026: bit.ly/CosmoFinancial… #BuildingHealthConfidence #Investors #Healthcare #Cosmo

𝗠𝗼𝗿𝗲 𝘁𝗵𝗮𝗻 𝟮𝟬,𝟬𝟬𝟬 𝗮𝘁𝘁𝗲𝗻𝗱𝗲𝗲𝘀 𝗮𝘁 #BIO2026! At @CosmoConfidence we proudly presented our #gastroenterology & #dermatology assets, forging new partnerships to advance patient care through innovation and collaboration. #Biotech #Innovation #Partnerships

𝗔𝘁 𝗕𝗜𝗢 𝗜𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗖𝗼𝗻𝘃𝗲𝗻𝘁𝗶𝗼𝗻 𝟮𝟬𝟮𝟲, it’s all about connection. We’re proud to be part of a global community united by a shared purpose: advancing science and improving patients’ lives. #BIO2026 #Partnerships #healthconfidence

#BuildingHealthConfidence through performance and vision. Our CEO @giovannidinapol and CFO Svetlana Sigalova will present the #HalfYear 2026 #FinancialResults, followed by an overview of our strategic priorities, growth opportunities and future #outlook.

Gut health is where Cosmo began. It never stopped being our frontier. We'll be at #BIO2026 in San Diego with our GI team. Schedule a meeting via BIO Partnering™ → partner.bio.org/conference/86/… #Gastroenterology #LifeSciences #BuildingHealthConfidence

#BIO2026 is just around the corner, and we’re heading to San Diego! Two of our experts will be there to connect, share insights on our latest innovations and explore what we can build together. 𝗦𝗰𝗵𝗲𝗱𝘂𝗹𝗲 𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 with us: partner.bio.org/conference/86/…

For three decades we’ve worked at the intersection of science, tech & AI to help patients and professionals live with confidence. None of this would have been possible without our amazing team of scientists, technologists and experts.

New research will be presented at @WCHRKorea Oral presentations by Dr. Maria Hordinsky: May 30 | 13:43-13:53 KST May 31 | 11:08-11:23 KST Poster presentations available May 28-31 The data presented is related to ongoing scientific research. #WCHR2026 #Dermatology

At Cosmo, our work in gut health starts here: with the real people behind every data point. Understanding IBD more deeply is how we move science forward. #IBDAwareness #IBDHasNoBorders #GutHealth

Crohn's Disease and Ulcerative Colitis cause symptoms others can't see — severe abdominal pain, persistent diarrhoea, extreme fatigue. But their effect on daily life, relationships and emotional wellbeing is profound.

IBD is invisible. Its impact isn't. On #WorldIBDDay, let's talk about what 5 million people live with every day.

CEO @giovannidinapol: "This milestone reflects both strong execution and a clear strategic focus [...] targeted delivery technologies designed to act locally at the site of disease." #ClinicalTrial #Gastroenterology #IBD

77 patients enrolled across 24 European sites, on schedule. Topline results expected fall 2026.

Patient enrolment complete. Our Phase II trial evaluating rifamycin enema — an investigational therapy for distal ulcerative colitis and ulcerative proctitis — has reached a key milestone. cosmohealthconfidence.com/news/91288300-…

We will be presenting new research at @SocInvestDerm #SIDChicago26. Poster #1054 Title: Clascoterone topical solution 5% modulates androgen receptor-regulated proteins in the secretory proteome of male pattern hair loss The data presented relate to ongoing scientific research.

#ICYMI: We announced positive 12-month data results from the SCALP 1 and SCALP 2 studies evaluating clascoterone 5% topical solution in male #HairLoss Read more: bit.ly/ClascoteroneSa… #Cosmo #ClinicalTrial #PatientCare #Innovation #AndrogeneticAlopecia

Our CFO, Svetlana Sigalova, will hold will hold virtual meetings with during the @𝗞𝗲𝗽𝗹𝗲𝗿 𝗖𝗵𝗲𝘂𝘃𝗿𝗲𝘂𝘅 𝗦𝘄𝗶𝘀𝘀 𝗦𝗲𝗺𝗶𝗻𝗮𝗿. Connect with us, please reach out to our #InvestorRelations team to arrange a meeting bit.ly/IRTeams #Cosmo #InvestorRelations

#DDW2026 reinforced the direction of innovation in gastrointestinal health. If you missed our poster presentation, you can view it here: bit.ly/eposterDDW It’s been great to see the field’s momentum continue to grow. #DDW2026 #Gastroenterology #Research #DigestiveHealth

Our CFO, Svetlana Sigalova, will hold one-to-one meetings with investors during the 𝗧𝗣 𝗜𝗖𝗔𝗣 𝗛𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲 𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 Connect with us, please reach out to our #InvestorRelations team to arrange a meeting bit.ly/IRTeams

#𝗗𝗗𝗪𝟮𝟬𝟮𝟲 is underway and we presented our poster: Low systemic absorption of rifamycin sv mmx® in compensated cirrhosis: a pharmacokinetic analysis of a double-blind, placebo-controlled trial.” The study explores the pharmacokinetic profile of rifamycin SV MMX®